SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

SAN

82.35

+0.83%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

719.2

-0.88%↓

FRE

48.76

+0.52%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

19.86 2.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.46

Max

20.4

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.47% upside

Turustatistika
By TradingEconomics
Turukapital	25M 932M
Eelmine avamishind	16.96
Eelmine sulgemishind	19.86

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. dets 2025, 23:54 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22. dets 2025, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Correction to Alphabet to Buy Intersect Article

22. dets 2025, 17:21 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22. dets 2025, 16:46 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion in Cash

22. dets 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22. dets 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22. dets 2025, 22:30 UTC

Tulu

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 21:37 UTC

Omandamised, ülevõtmised, äriostud

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22. dets 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Acquire Prospective Package From Tempest Minerals

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22. dets 2025, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22. dets 2025, 20:52 UTC

Omandamised, ülevõtmised, äriostud

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22. dets 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22. dets 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22. dets 2025, 19:49 UTC

Omandamised, ülevõtmised, äriostud

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22. dets 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22. dets 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22. dets 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22. dets 2025, 18:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22. dets 2025, 18:23 UTC

Omandamised, ülevõtmised, äriostud

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22. dets 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22. dets 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

22.47% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 22.47%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.